Cancer targets in the Ras pathway.
暂无分享,去创建一个
F. McCormick | K. Oda | K. Rauen | P. Rodriguez-Viciana | O. Tetsu | K. Oda | J. Okada | F McCormick | P Rodriguez-Viciana | O Tetsu | K Oda | J Okada | K Rauen
[1] R. Kucherlapati,et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. , 1997, Genes & development.
[2] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[3] Chris Albanese,et al. NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1 , 1999, Molecular and Cellular Biology.
[4] M. Malumbres,et al. Targeted Genomic Disruption of H-ras and N-ras, Individually or in Combination, Reveals the Dispensability of Both Loci for Mouse Growth and Development , 2001, Molecular and Cellular Biology.
[5] C. Albanese,et al. Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*) , 1995, The Journal of Biological Chemistry.
[6] Claus Scheidereit,et al. NF-κB Function in Growth Control: Regulation of Cyclin D1 Expression and G0/G1-to-S-Phase Transition , 1999, Molecular and Cellular Biology.
[7] W. Kabsch,et al. Guanosine triphosphatase stimulation of oncogenic Ras mutants. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[8] Frank Petersen,et al. Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .
[9] E. Zackai,et al. HRAS mutation analysis in Costello syndrome: Genotype and phenotype correlation , 2006, American journal of medical genetics. Part A.
[10] M. Teitell,et al. Mutations in Costello Syndrome : Detection of Constitutional Activating Mutations in Codon 12 and 13 and Loss of Wild-Type Allele in Malignancy , 2005 .
[11] D. Pinkel,et al. Genomic approaches to skin cancer diagnosis. , 2001, Archives of dermatology.
[12] C. Albanese,et al. Epidermal Growth Factor and c-Jun Act via a Common DNA Regulatory Element to Stimulate Transcription of the Ovine P-450 Cholesterol Side Chain Cleavage (CYP11A1) Promoter (*) , 1995, The Journal of Biological Chemistry.
[13] Frank McCormick,et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. , 2005, Cancer research.
[14] Frank McCormick,et al. The GTPase superfamily: conserved structure and molecular mechanism , 1991, Nature.
[15] W. Reardon,et al. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases , 2005, Journal of Medical Genetics.
[16] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[17] L. Augenlicht,et al. Cyclin D1 Genetic Heterozygosity Regulates Colonic Epithelial Cell Differentiation and Tumor Number in ApcMin Mice , 2004, Molecular and Cellular Biology.
[18] Kam Y. J. Zhang,et al. Germline KRAS mutations cause Noonan syndrome , 2006, Nature Genetics.
[19] E. Pai,et al. The structure of Ras protein: a model for a universal molecular switch. , 1991, Trends in biochemical sciences.
[20] F. McCormick,et al. Signaling Specificity by Ras Family GTPases Is Determined by the Full Spectrum of Effectors They Regulate , 2004, Molecular and Cellular Biology.
[21] Yukichi Tanaka,et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome , 2005, Nature Genetics.
[22] E. Bossy‐Wetzel,et al. Cell cycle‐dependent variations in c‐Jun and JunB phosphorylation: a role in the control of cyclin D1 expression , 2000, The EMBO journal.
[23] Pablo Rodriguez-Viciana,et al. Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome , 2006, Science.
[24] Frank McCormick,et al. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.